Stock Yards Bank & Trust Co. Cuts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stock Yards Bank & Trust Co. reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,777 shares of the medical research company’s stock after selling 146 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $3,597,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Significant Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $400,000. Diversified LLC lifted its holdings in Thermo Fisher Scientific by 4.3% during the fourth quarter. Diversified LLC now owns 782 shares of the medical research company’s stock valued at $415,000 after purchasing an additional 32 shares during the last quarter. Jennison Associates LLC lifted its holdings in Thermo Fisher Scientific by 0.7% during the fourth quarter. Jennison Associates LLC now owns 83,485 shares of the medical research company’s stock valued at $44,313,000 after purchasing an additional 564 shares during the last quarter. Telemus Capital LLC lifted its holdings in Thermo Fisher Scientific by 5.0% during the fourth quarter. Telemus Capital LLC now owns 19,921 shares of the medical research company’s stock valued at $10,574,000 after purchasing an additional 942 shares during the last quarter. Finally, Duality Advisers LP purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $2,024,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Royal Bank of Canada increased their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, The Goldman Sachs Group increased their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Stock Up 0.7 %

TMO stock opened at $548.37 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company’s 50 day moving average is $571.30 and its 200 day moving average is $528.18. The stock has a market cap of $209.32 billion, a price-to-earnings ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period last year, the business earned $5.40 earnings per share. The business’s quarterly revenue was down 4.9% on a year-over-year basis. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.